On December 8, 2019, the inaugural meeting of the Chinese Society of Clinical Oncology (CSCO) Oncology Cardiology Expert Committee was held in the beautiful Dalian. The meeting was chaired by Liu Ling, director of the CSCO office, and the experts were voted for, Professor Liu Jiwei was elected as the chairman, and Professor Xia Yunlong was the chairman-designate; Professor Chu Xiaoyuan, Professor Huang Jing, Professor Pan Hongming, Professor Pan Yueyin, Professor Shu Yongqian, Professor Sun Tao and Professor Wu Gang were elected as vice chairmen; Professor Fang Fengqi was elected Secretary-General; Professor Ma Jun and Professor Qin Shukui are the advisors of the committee. Zhang Min, chairman of Mengyang Pharmaceutical, was elected as a standing member of the CSCO Oncology Cardiology Expert Committee.

Liu Ling, Director of CSCO Office, delivered a speech

At the beginning of the meeting, Director Liu Ling of CSCO Office made a speech, she said that she was very happy to come to the beautiful Dalian to participate in the conference, Director Liu Ling first gave a brief introduction to CSCO from the establishment of CSCO, purpose and principles, main tasks, organizational structure, CSCO guideline formulation, international exchange activities, fund management, etc. She mentioned that the main tasks of CSCO: a. Carry out continuing education, train professional oncology talents, and update clinical oncology knowledge and technology; Two. Organize and coordinate multi-center, multi-disciplinary, and multi-level collaborative research in clinical oncology in accordance with GCP norms; Three. Establish close ties with relevant academic groups and cancer prevention and treatment organizations at home and abroad, promote international scientific and technological cooperation, and promote friendly exchanges at home and abroad; Four. Recommend and reward excellent academic papers and books, and support the publication of professional books on clinical oncology; Five. Actively carry out publicity and education on cancer prevention and treatment; Six. Serve as a link between the government and the health administration department to connect cancer clinicians and an assistant to carry out cancer prevention and treatment work. At the same time, Director Liu Ling emphasized that since the establishment of CSCO, great progress has been made in the development of academic conferences and continuing education activities, the formulation of CSCO guidelines and fund management, for example, the CSCO guidelines are different from foreign guidelines, it takes into account the differences in medical resources in China, the accessibility of resources and the value of tumor treatment, and is more suitable for Chinese clinicians, and has become a pocket book for many clinicians. Since its establishment, CSCO has actively carried out international exchanges, established good relations with international cancer societies such as the European Society of Clinical Oncology, and more and more Chinese scholars have presented China's clinical research results on the international academic stage.

Professor Liu Jiwei, chairman of the committee, delivered a speech

Professor Liu Jiwei, chairman of the Oncology Cardiology Expert Committee of the Chinese Society of Clinical Oncology, delivered a speech on the background and future planning of the CSCO Oncology Cardiology Expert Committee, he said that he was honored to be elected as the chairman of the committee, he pointed out that the current effect of tumor treatment is very good, but 1/3 of patients will be accompanied by heart disease in the later stage, so oncology cardiology came into being as an interdisciplinary discipline. Professor Liu Jiwei focused on the background of the establishment and development of the CSCO Oncology and Cardiology Expert Committee, and pointed out that preventing or avoiding cardiotoxicity caused by tumor treatment is the focus of future work, and early detection, early diagnosis and early treatment should be achieved. In terms of overall planning, he said that he will conduct in-depth discussions and studies with relevant experts on the development of multi-center clinical trials and real-world studies, the formulation of consensus and guidelines, and the CSCO guideline tour, and hopes that with the joint efforts of everyone, the Oncology Cardiology Expert Committee of the Chinese Society of Clinical Oncology will have new developments in the future.

As an emerging interdisciplinary discipline in the world, oncology cardiology has received more and more attention in the field of oncology and cardiovascular diseases in recent years. With the continuous deepening of oncology and cardiology research, the Chinese Oncology Cardiology Conference has lasted for four years! The content of this year's conference explores the scientific theory, clinical practice and hot topics in the field of oncology and cardiology from a multi-dimensional, high-level and all-round perspective, and continues to strive to build a unique brand in the field of oncology and cardiology in China.

The establishment of the CSCO Oncology Cardiology Expert Committee marks a new milestone in oncology and cardiology in China。

Zhang Min (right), chairman of Mengyang Pharmaceutical, and Professor Liu Jiwei (left), chairman of the CSCO Oncology Cardiology Expert Committee, took a group photo

Group photo of experts at the inaugural meeting of the Oncology Expert Committee of the Chinese Society of Clinical Oncology (CSCO).

★ The company's research and development of 1.1 class chemical drugs, "Schizandra B tablets" project introduction:

Schizandra B tablets are innovative drugs with independent intellectual property rights developed by our company. According to the announcement of the Food and Drug Administration on the issuance of the "Work Plan for the Reform of the Registration and Classification of Chemical Drugs (No. 51 of 2016)", Schizandra B tablets are innovative drugs that have not been marketed in China or abroad, and their structure is clear and can reduce the incidence and severity of cardiotoxicity caused by doxorubicin. This project has obtained 6 authorized patents at home and abroad. At present, the company has submitted a clinical application to CDE for Class 1 new drugs according to chemical drugs.